截至2024年年报，微创医疗营业总收入74.12亿元、净利润-15.39亿元。 本文源自：金融界 作者：行情君 8月8日，微创医疗(00853)盘中下跌5.62%，截至15:28，报13.09元/股，成交5.06亿元。 微创医疗科学有限公司是一家跨国企业集团，专注于心血管、脑血管、神经系统、骨科学等多个领域的 创新医疗技术，致力于提供普惠化的医疗解决方案。公司在全球多个地区设有创新中心和生产基地，产 品已进入全球超过100个国家和地区，帮助挽救和延长生命。 ...

Core Viewpoint - MicroPort Medical is experiencing a decline in stock price, reflecting potential challenges in its financial performance and market perception [1]. Financial Performance - As of the 2024 annual report, MicroPort Medical reported total revenue of 7.412 billion yuan and a net loss of 1.539 billion yuan [2]. Market Activity - On August 1, MicroPort Medical's stock price fell by 2.11%, reaching 13.92 yuan per share, with a trading volume of 604 million yuan [1]. Company Overview - MicroPort Medical is a multinational enterprise focused on innovative medical technologies across various fields, including cardiovascular, neurovascular, and orthopedic sectors [1]. - The company aims to provide accessible medical solutions and has established innovation centers and production bases in multiple regions globally, with products available in over 100 countries [1].

Core Viewpoint - MicroPort Medical is a multinational enterprise focused on innovative medical technologies across various fields, including cardiovascular, cerebrovascular, nervous system, and orthopedics, aiming to provide accessible medical solutions [1][2]. Group 1: Company Performance - As of the 2024 annual report, MicroPort Medical reported total revenue of 7.412 billion yuan and a net loss of 1.539 billion yuan [2]. Group 2: Market Activity - On July 31, MicroPort Medical's stock price increased by 2.38%, reaching 14.64 yuan per share, with a trading volume of 330 million yuan [1].